|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Erhard F, Haas J, Lieber D, Malterer G,
Jaskiewicz L, Zavolan M, Dölken L and Zimmer R: Widespread context
dependency of microRNA-mediated regulation. Genome Res. 24:906–919.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
7
|
Tong AW and Nemunaitis J: Modulation of
miRNA activity in human cancer: A new paradigm for cancer gene
therapy? Cancer Gene Ther. 15:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stevanato L and Sinden JD: The effects of
microRNAs on human neural stem cell differentiation in two- and
three-dimensional cultures. Stem Cell Res Ther. 5:492014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nam EJ, Yoon H, Kim SW, et al: MicroRNA
expression profiles in serous ovarian carcinoma. Clin Cancer Res.
14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li C, Feng Y, Coukos G and Zhang L:
Therapeutic microRNA strategies in human cancer. AAPS J.
11:747–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang XH, Chen JS, Wang Q, Chen XL, Wen L,
Chen LZ, Bi J, Zhang LJ, Su Q and Zeng WT: miR-338–3p suppresses
invasion of liver cancer cell by targeting smoothened. J Pathol.
225:463–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu X, Tan D, Hou Z, Hu Z, Liu G, Ouyang Y
and Liu F: The effect of miR-338-3p on HBx deletion-mutant
(HBx-d382) mediated liver-cell proliferation through CyclinD1
regulation. PLoS One. 7:e432042012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Pan M, Han L, Lu H, Hao X and Dong
Q: miR-338-3p suppresses neuroblastoma proliferation, invasion and
migration through targeting PREX2a. FEBS Lett. 587:3729–3737. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caramuta S, Egyházi S, Rodolfo M, Witten
D, Hansson J, Larsson C and Lui WO: MicroRNA expression profiles
associated with mutational status and survival in malignant
melanoma. J Invest Dermatol. 130:2062–2070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li P, Chen X, Su L, Li C, Zhi Q, Yu B,
Sheng H, Wang J, Feng R, Cai Q, et al: Epigenetic silencing of
miR-338-3p contributes to tumorigenicity in gastric cancer by
targeting SSX2IP. PLoS One. 8:e667822013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun K, Su G, Deng H, Dong J, Lei S and Li
G: Relationship between miRNA-338-3p expression and progression and
prognosis of human colorectal carcinoma. Chin Med J (Engl).
127:1884–1890. 2014.
|
|
23
|
Sun K, Deng HJ, Lei ST, Dong JQ and Li GX:
miRNA-338-3p suppresses cell growth of human colorectal carcinoma
by targeting smoothened. World J Gastroenterol. 19:2197–2207. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang S, Lu Z, Unruh AK, et al: Clinically
relevant microRNAs in ovarian cancer. Mol Cancer Res. Oct
10–2014.(Epub ahead of print). pii: molcanres.0424.2014. PubMed/NCBI
|
|
25
|
Kinose Y, Sawada K, Nakamura K and Kimura
T: The role of microRNAs in ovarian cancer. BioMed Res Int.
2014:2493932014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan
C, Liu S and Zhang Y: MiR-338-3p inhibits hepatocarcinoma cells and
sensitizes these cells to sorafenib by targeting hypoxia-induced
factor 1α. PLoS One. 9:e1155652014. View Article : Google Scholar
|
|
27
|
Li W, Xu S, Lin S and Zhao W:
Overexpression of runt-related transcription factor-2 is associated
with advanced tumor progression and poor prognosis in epithelial
ovarian cancer. J Biomed Biotechnol. 2012:4565342012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Q, Liu H, Lin H, Yuan G, Zhang L and
Chen Z: MicroRNA-338-3p promotes differentiation of mDPC6T into
odontoblast-like cells by targeting Runx2. Mol Cell Biochem.
377:143–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu H, Sun Q, Wan C, Li L, Zhang L and
Chen Z: MicroRNA-338-3p regulates osteogenic differentiation of
mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2.
J Cell Physiol. 229:1494–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Komori T, Yagi H, Nomura S, Yamaguchi A,
Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al:
Targeted disruption of Cbfa1 results in a complete lack of bone
formation owing to maturational arrest of osteoblasts. Cell.
89:755–764. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Onodera Y, Miki Y, Suzuki T, Takagi K,
Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, et al:
Runx2 in human breast carcinoma: Its potential roles in cancer
progression. Cancer Sci. 101:2670–2675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brubaker KD, Vessella RL, Brown LG and
Corey E: Prostate cancer expression of runt-domain transcription
factor Runx2, a key regulator of osteoblast differentiation and
function. Prostate. 56:13–22. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li H, Zhou RJ, Zhang GQ and Xu JP:
Clinical significance of RUNX2 expression in patients with nonsmall
cell lung cancer: A 5-year follow-up study. Tumour Biol.
34:1807–1812. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martin JW, Zielenska M, Stein GS, van
Wijnen AJ and Squire JA: The role of RUNX2 in osteosarcoma
oncogenesis. Sarcoma. 2011:2827452011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niu DF, Kondo T, Nakazawa T, Oishi N,
Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor
Runx2 is a regulator of epithelial-mesenchymal transition and
invasion in thyroid carcinomas. Lab Invest. 92:1181–1190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kayed H, Jiang X, Keleg S, Jesnowski R,
Giese T, Berger MR, Esposito I, Löhr M, Friess H and Kleeff J:
Regulation and functional role of the Runt-related transcription
factor-2 in pancreatic cancer. Br J Cancer. 97:1106–1115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang ZQ, Keita M, Bachvarova M, Gobeil S,
Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Trinh
XB, et al: Inhibition of RUNX2 transcriptional activity blocks the
proliferation, migration and invasion of epithelial ovarian
carcinoma cells. PLoS One. 8:e743842013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tandon M, Chen Z and Pratap J: Runx2
activates PI3K/Akt signaling via mTORC2 regulation in invasive
breast cancer cells. Breast Cancer Res. 16:R162014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tandon M, Chen Z and Pratap J: Role of
Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in
MCF-10A cells. J Cell Biochem. 115:2208–2217. 2014. View Article : Google Scholar : PubMed/NCBI
|
